menu ☰
menu ˟

Baricitinib 4 mg linked to SLE improvements

23 Oct 2018
CHICAGO — Among patients with systemic lupus erythematosus, a daily 4-mg dose of baricitinib was associated with significant clinical improvements compared with placebo, with an acceptable risk-benefit profile, according to data presented at the AC...

Click here to view the full article which appeared in Rheumatology

Please note

The news articles accessible on the Health Well website have been compiled from various sources that are not controlled by the Institute of Public Health in Ireland (IPH). IPH is therefore not responsible for the content of external websites and the inclusion of a link to an external website from the Health Well should not be understood to be an endorsement of that website.